Evidence map›Paper›PMID 41843169›Full record

ArticleCancer immunology, immunotherapy : CII2026

RIPK1 as a potential target to augment DC efficacy in tumor immunotherapy.

Lin Mao, Yangjing Ou, Yuchao Zhang, Minghui Wang, Guoqing Dong, Asma Khanniche, Hailong Wang, Zhenchuan Wu, Haibing Zhang, Landian Hu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lin MaoShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Yangjing OuShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Yuchao ZhangShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Minghui WangShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
Guoqing DongSchool of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Asma KhannicheANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China.
Hailong WangANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China.
Zhenchuan WuANDA Biology Medicine Development (BeiJing) Co., Ltd, Beijing, China.
Haibing ZhangShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. hbzhang@sinh.ac.cn.
Landian HuShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. ldhu2013@163.com.
Xiangyin KongShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. xykong@sinh.ac.cn.

Funding

Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0552310the Global Common Challenges Project of the Chinese Academy of Sciences 176GJHZ2023038GCthe National Key Research and Development Program of China 2021YFA080521the National Key Research and Development Program of China 2022YFA080730
6 · The paper itself

Abstract

Dendritic Cell (DC)-based vaccine is a tumor immunotherapy approach with great potential, and improving the efficacy is an urgent problem to be solved. RIPK1 is an important regulator of inflammation and cell death, and may play a significant role in the tumor immune function of DCs. Our study found that DC-specific knockout of Ripk1 can inhibit tumor growth in mice by increasing DC immune infiltration and strengthening the interactions with cytotoxic T cells in the tumor microenvironment. The efficacy of DC-specific Ripk1 knockout was also validated in in vitro experiments, revealing the function of the Ripk1 knockout involved augment of antigen presentation capacity and activation status of DCs and their ability to activate Cd8

Indexed as

Cancer VaccinesDendritic CellsImmunotherapyNeoplasmsReceptor-Interacting Protein Serine-Threonine KinasesAnimalsCD8-Positive T-LymphocytesFemaleHumansMiceMice, Inbred C57BLMice, KnockoutT-Lymphocytes, CytotoxicTumor MicroenvironmentCancer VaccinesReceptor-Interacting Protein Serine-Threonine KinasesRipk1 protein, mouseDC vaccineRIPK1Tumor immunotherapyTumor microenvironment

Identifiers

PMID41843169
PMCPMC12996472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.